DESCRIPTION/OVERVIEW
The Cleveland Clinic Metabolic Dysfunction-Associated Steatohepatitis “MASH” Conference is the first truly multidisciplinary educational summit dedicated to MASH care. While prior conferences have focused primarily on gastroenterology and hepatology audiences, this event brings together a broad range of specialties – including hepatology, transplant surgery, endocrinology, bariatric surgery, cardiology, and oncology – to address the entire spectrum of disease and the whole patient.
Attendees will gain insights spanning early metabolic dysfunction to advanced liver disease, organ failure, and transplantation, with a focus on collaborative, patient-centered approaches that reflect the future of MASH care.
FEATURED TOPICS
- MASLD/MASH – Burden, Diagnosis, and Clinical Implications
- Treatment of MASH Across the Disease Spectrum
- Translational Science and Clinical Research in MASH
- Transplant Candidacy, Risk Stratification, and Outcomes in MASH
- Complex and Multi-Organ Transplant Decision-Making in MASH
- MASH and Cancer (HCC, CCA)
- Non-CME Hands On Symposium
WHO SHOULD ATTEND
This course is designed for gastroenterologists, hepatologists, bariatric, transplant, and general surgeons, as well as endocrinologists, oncologists, and primary care physicians.
EDUCATIONAL OBJECTIVES
- Describe current and emerging strategies for the prevention, screening, diagnosis, and treatment of MASH across the full disease spectrum, from early metabolic dysfunction to cirrhosis, liver transplantation, and post-transplant care.
- Apply evidence-based approaches to diagnose and manage coexisting cardiometabolic diseases, including type 2 diabetes, dyslipidemia, and cardiovascular disease with particular attention to reducing major adverse cardiovascular events (MACE), the leading cause of death in patients with MASH.
- Identify critical knowledge gaps and outline future directions in MASH research, policy, and clinical practice, emphasizing the need for cross-disciplinary collaboration and innovation.
- Evaluate integrated care delivery models that combine medical, surgical, behavioral digital (AI based), and value-based approaches to improve access, equity, and outcomes in MASH—with focused attention to high-risk populations such as living liver donors with obesity and MASLD, patients with severe obesity and decompensated cirrhosis undergoing transplant, individuals requiring combined cardiothoracic and liver transplantation, and those with MASH-HCC beyond conventional transplant criteria.